Platelet Transfusion Refractoriness — ACERTP

Platelet Transfusion Refractoriness Clinical Trial

Official title:
Characterization of Anti-HLA I Antibodies Involved in Platelet Transfusion Refractoriness: Optimization of the Transfusion Management of Patients With Severe Thrombocytopenia

Status Recruiting

Clinical Trial Summary

Platelet Transfusion Refractoriness is one of the severe complications after multiple transfusions in patients with severe thrombopenia. Platelet Transfusion Refractoriness is characterized by inefficient transfusion and arise from allo-antibodies specific of platelets antigenes, mostly carried by HLA-I molecules.

Clinical Trial Description

A preliminary study has shown different isotypes of anti-HLA I in patients with Platelet Transfusion Refractoriness. Our hypothesis is that the type of anti-HLA I antibodies (recognised epitope, quantity, isotype) should establish predictive and diagnostic criteria for Platelet Transfusion Refractoriness. ;

Study Design

Related Conditions & MeSH terms

Platelet Transfusion Refractoriness

Clinical Trial Details

NCT number	NCT05399693
Study type	Observational
Source	Institut de cancérologie Strasbourg Europe
Contact	Manon VOEGELIN
Phone	03 68 33 95 23
Email	promotion-rc@icans.eu
Status	Recruiting
Phase
Start date	February 2, 2022
Completion date	November 2, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05761457` - Efficacy and Safety of Autologous Cryopreserved Platelets in Patients With PTR	N/A
Completed	`NCT02858323` - Complement (C1q) Binding to HLA Antibodies in a Solid-phase Immunoassay and Clinical Effect on Platelet Transfusion
Recruiting	`NCT06254560` - Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness	Phase 2
Recruiting	`NCT04846439` - Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL	Phase 1/Phase 2
Recruiting	`NCT05832216` - Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients With Aplastic Anemia	Phase 1